By Associate Professor Marianne Kate Martinello

Preprints

Koopsen J; Matthews G; Rockstroh JK; Applegate TL; Bhagani SR; Grebely J; Rauch A; Sacks-Davis R; Ingiliz P; Boesecke C; Rebers S; Feld J; Bruneau J; Martinello M; Hellard ME; Dore GJ; Schinkel J; van der Valk M; Group RS, 2022, Hepatitis C Virus Transmission Dynamics in a Global Cohort of Men Who Have Sex with Men with Recently Acquired Infection, http://dx.doi.org/10.2139/ssrn.4125248

Hosseini-Hooshyar S; Hajarizadeh B; Bajis S; Law M; Janjua N; fierer D; Chromy D; Rockstroh JK; Martin T; Ingiliz P; Hung C-C; Dore GJ; Martinello M; Matthews G, 2021, Hepatitis C Reinfection Risk Following Successful Therapy Among People Living with HIV: A Global Systematic Review, Meta-Analysis, and Meta-Regression, http://dx.doi.org/10.2139/ssrn.3958916

Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson S; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer D; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA, 2021, Maintenance of Broad Neutralising Antibodies and Memory B Cells 12 Months Post-Infection Is Predicted by SARS-CoV-2 Specific CD4+ T Cell Responses, http://dx.doi.org/10.2139/ssrn.3920641

Abayasingam A; Balachandran H; Agapiou D; Rodrigo C; Keoshkerian E; Li H; Brasher N; Christ D; Rouet R; Burnett D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Brilot F; Mina M; Post JJ; Hudson B; Gilroy N; Dwyer D; Sasson S; Tea F; Pilli D; Tedla N; Lloyd AR; Martinello M; Bull RA; Group CS, 2020, Long-Term Persistence of Neutralizing Memory B Cells in SARS-CoV-2, http://dx.doi.org/10.2139/ssrn.3732365

Martinello M; Yee J; Bartlett SR; Read P; Baker D; Post J; Finlayson R; Bloch M; Doyle J; Shaw D; Rowling D; Doong N; Jackson E; Hellard M; Petoumenos K; Lin L; Marks P; Applegate T; Dore GJ; Matthews GV, 2018, Moving Towards HCV Elimination Among People Living with HIV in Australia: Analysis of the CEASE Prospective Cohort Study, http://dx.doi.org/10.2139/ssrn.3269607

Baird S; Ashley CL; Marsh-Wakefield F; Alca S; Ashhurst TM; Ferguson AL; Lukeman H; Counoupas C; Post JJ; Konecny P; Bartlett A; Martinello M; Bull RA; Lloyd A; Grey A; Hutchings O; Palendira U; Britton WJ; Steain M; Triccas JA, A unique cytotoxic CD4+ T cells signature defines critical COVID-19, http://dx.doi.org/10.1101/2023.02.17.23286059

Rouet R; Henry JY; Johansen MD; Sobti M; Balachandran H; Langley DB; Walker G; Lenthall H; Jackson J; Ubiparipovic S; Mazigi O; Schofield P; Burnett DL; Brown SHJ; Martinello M; Hudson B; Gilroy N; Post JJ; Kelleher A; Jäck H-M; Goodnow CC; Turville SG; Rawlinson WD; Bull RA; Stewart AG; Hansbro PM; Christ D, Broadly neutralizing SARS-CoV-2 antibodies through epitope-based selection from convalescent patients, http://dx.doi.org/10.1101/2022.10.19.512954

Carson JM; Barbieri S; Verich A; Tu E; Lloyd A; Dore GJ; Matthews GV; Martinello M, Development of a machine learning model to predict short duration HCV treatment response, http://dx.doi.org/10.1101/2025.09.19.25336147

Bull R; Abayasingam A; Balachandran H; Agapiou D; Rodrigo C; Keoshkerian E; Li H; Brasher N; Christ D; Rouet R; Burnett D; Grubor-Bauk B; Rawlinson W; Turville S; Aggarwal A; Brilot F; Mina M; Post J; Hudson B; Gilroy N; Dwyer D; Sasson S; Tea F; Pilli D; Tedla N; Lloyd A; Martinello M, Long-term persistence of neutralizing memory B cells in SARS-CoV-2, http://dx.doi.org/10.21203/rs.3.rs-92527/v1

Adhikari A; Abayasingam A; Rodrigo C; Agapiou D; Pandzic E; Brasher NA; Fernando BSM; Keoshkerian E; Li H; Kim HN; Lord M; Popovic G; Rawlinson W; Mina M; Post JJ; Hudson B; Gilroy N; Bartlett AW; Ahlenstiel G; Grubor-Bauk B; Dwyer D; Konecny P; Lloyd AR; Martinello M; Bull RA; Tedla N, Longitudinal characterisation of phagocytic and neutralisation functions of anti-Spike antibodies in plasma of patients after SARS-CoV-2 infection, http://dx.doi.org/10.1101/2021.12.21.473774

Nyein PP; Haskelberg H; Martinello M; Lowe M; Goodman-Meza D; Avihingsanon A; Kelleher AD; Rodgers A; Schutte AE; Nnakelu EC; Byakwaga H; Trevillyan J; Losso M; Kumarasamy N; Azwa RISR; Kaplan R; Clifton B; Arnott C; Dharan NJ; Petoumenos K; Matthews GV, Optimizing Metabolic Management on Integrase-based ART (OPTIMAR): study protocol for a 2x2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk, http://dx.doi.org/10.21203/rs.3.rs-7648678/v1

Back to profile page